NCT03445208View on ClinicalTrials.gov

A Study of Experimental Medication BMS-986036 Given to Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 14, 2018

Primary Completion Date

May 2, 2018

Study Completion Date

May 2, 2018

Conditions
Hepatic CirrhosisLiver FibrosisNonalcoholic Fatty Liver DiseaseNonalcoholic Steatohepatitis
Interventions
DRUG

BMS-986036

Crossover administration to abdomen then upper arm

Trial Locations (1)

84107

PRA Health Sciences, Salt Lake City

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY